JP6351629B2 - 点眼用組成物 - Google Patents

点眼用組成物 Download PDF

Info

Publication number
JP6351629B2
JP6351629B2 JP2015555360A JP2015555360A JP6351629B2 JP 6351629 B2 JP6351629 B2 JP 6351629B2 JP 2015555360 A JP2015555360 A JP 2015555360A JP 2015555360 A JP2015555360 A JP 2015555360A JP 6351629 B2 JP6351629 B2 JP 6351629B2
Authority
JP
Japan
Prior art keywords
compound
composition
disclosed
compositions
buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015555360A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016506931A5 (cg-RX-API-DMAC7.html
JP2016506931A (ja
Inventor
ホン レン
ホン レン
トーマス サン
トーマス サン
Original Assignee
ライジェル ファーマシューティカルズ, インコーポレイテッド
ライジェル ファーマシューティカルズ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ライジェル ファーマシューティカルズ, インコーポレイテッド, ライジェル ファーマシューティカルズ, インコーポレイテッド filed Critical ライジェル ファーマシューティカルズ, インコーポレイテッド
Publication of JP2016506931A publication Critical patent/JP2016506931A/ja
Publication of JP2016506931A5 publication Critical patent/JP2016506931A5/ja
Application granted granted Critical
Publication of JP6351629B2 publication Critical patent/JP6351629B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A61K31/79—Polymers of vinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015555360A 2013-01-24 2014-01-24 点眼用組成物 Expired - Fee Related JP6351629B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361756306P 2013-01-24 2013-01-24
US61/756,306 2013-01-24
PCT/US2014/013036 WO2014117010A2 (en) 2013-01-24 2014-01-24 Composition for ophthalmic administration

Publications (3)

Publication Number Publication Date
JP2016506931A JP2016506931A (ja) 2016-03-07
JP2016506931A5 JP2016506931A5 (cg-RX-API-DMAC7.html) 2017-03-02
JP6351629B2 true JP6351629B2 (ja) 2018-07-04

Family

ID=50102221

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015555360A Expired - Fee Related JP6351629B2 (ja) 2013-01-24 2014-01-24 点眼用組成物

Country Status (5)

Country Link
US (1) US20140206708A1 (cg-RX-API-DMAC7.html)
EP (1) EP2948130B1 (cg-RX-API-DMAC7.html)
JP (1) JP6351629B2 (cg-RX-API-DMAC7.html)
CA (1) CA2898644A1 (cg-RX-API-DMAC7.html)
WO (1) WO2014117010A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9463201B2 (en) * 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
WO2017178892A2 (en) 2016-04-14 2017-10-19 M.G. Therapeutics Ltd. Selenium disulfide compositions for use in treating meibomian gland dysfunction
CN107805212B (zh) * 2017-11-03 2021-08-20 宿迁德威化工股份有限公司 一种2-甲基-5-氨基苯磺酰胺的制备方法
EP4087655A4 (en) 2020-01-10 2024-02-21 Azura Ophthalmics Ltd INSTRUCTIONS FOR COMPOSITION AND SENSITIVITY

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1227128A (en) * 1916-11-06 1917-05-22 Ohio Blower Company Conveying mechanism.
ZA815175B (en) * 1980-08-01 1982-09-29 Smith & Nephew Ass Pharmaceutical composition
HU207222B (en) * 1990-02-15 1993-03-29 Chinoin Gyogyszer Es Vegyeszet Process for producing eyedrops containing primycin
CN1230882A (zh) * 1996-09-20 1999-10-06 博士伦公司 再湿润隐形眼镜和减轻眼部干燥的方法和组合物
JP5000835B2 (ja) * 2000-08-25 2012-08-15 千寿製薬株式会社 水性懸濁液剤
US20040198829A1 (en) * 2001-04-23 2004-10-07 Sponsel William Eric Prostanoids augment ocular drug penetration
WO2008011836A2 (es) * 2006-07-25 2008-01-31 Osmotica Corp. Soluciones oftálmicas
WO2010008883A1 (en) * 2008-06-24 2010-01-21 Qlt Plug Delivery, Inc. Combination treatment of glaucoma
CN102271915B (zh) * 2008-11-04 2014-11-26 巴斯夫欧洲公司 复合箔作为氧化敏感性聚合物的包装材料的用途,包装氧化敏感性聚合物的方法以及含有所述复合箔的包装
MX337849B (es) * 2009-07-28 2016-03-09 Rigel Pharmaceuticals Inc Composiciones y metodos para inhibicion de la via jak.
EP2595603A1 (en) * 2010-07-21 2013-05-29 Alcon Research, Ltd. Pharmaceutical composition with enhanced solubility characteristics

Also Published As

Publication number Publication date
WO2014117010A3 (en) 2015-01-29
JP2016506931A (ja) 2016-03-07
CA2898644A1 (en) 2014-07-31
EP2948130A2 (en) 2015-12-02
US20140206708A1 (en) 2014-07-24
WO2014117010A2 (en) 2014-07-31
EP2948130B1 (en) 2019-03-13

Similar Documents

Publication Publication Date Title
KR101740076B1 (ko) Jak 경로의 억제를 위한 조성물 및 방법
EP2788028B1 (en) Topical formulation for administering a compound
JP2018115205A (ja) 白斑の治療法
KR101802011B1 (ko) 원반성 루푸스에 사용하기 위한 2,4 치환 피리미딘디아민
EP2948130B1 (en) Composition for ophthalmic administration
US20190328753A1 (en) Compositions and methods for treating ocular diseases
JP2005047909A (ja) ピペリジン誘導体を有効成分とする掻痒治療剤
WO2019140207A1 (en) Compositions and methods for treating ocular diseases
CN106456641A (zh) 眼后段疾病的预防或治疗剂
HK1193746B (en) 2,4 substituted pyrimidinediamines for use in discoid lupus
HK1193746A (en) 2,4 substituted pyrimidinediamines for use in discoid lupus
JP2021500346A (ja) Ret9及びvegfr2阻害剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170913

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180509

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180605

R150 Certificate of patent or registration of utility model

Ref document number: 6351629

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees